Keyphrases
Breast Cancer
100%
Tumor-infiltrating Lymphocytes
72%
Peruvian
37%
Oncology Biomarkers
28%
Immuno-oncology
28%
Triple-negative Breast Cancer
25%
Breast Cancer Patients
22%
Breast Cancer Subtypes
22%
Indigenous Americans
21%
PIK3CA mutation
21%
Stromal Tumor-infiltrating Lymphocytes
21%
Residual Disease
19%
Glioblastoma
19%
Human Epidermal Growth Factor Receptor 2 (HER2)
19%
Tumor-infiltrating Immune Cells
18%
Phase II Trial
18%
Early Breast Cancer
17%
Peru
16%
Overall Survival
14%
Pathologist
12%
Clinical Trials
12%
Odds Ratio
12%
Programmed Death-ligand 1 (PD-L1)
12%
Neoadjuvant
11%
Cancer Control
11%
Neoadjuvant Therapy
11%
Prognostic Information
10%
Tumor
10%
Confidence Interval
10%
Malignancy
10%
Risk Management
10%
Prognostic Factors
10%
Triple Negative
10%
Neoadjuvant Chemotherapy
10%
Anthracyclines
9%
Lymphocyte Level
9%
MINDACT
9%
Genomic Risk
9%
CD163
9%
EORTC
9%
Docetaxel
9%
Hereditary Breast Cancer
9%
Hereditary Ovarian Cancer
9%
Genetic Epidemiology
9%
Gene Expression Profiling
9%
Intestine
9%
Capecitabine
9%
Pathogenic Variants
9%
Ancestry-specific
9%
Carcinoma in Situ
9%
Ketogenesis
9%
Regulatory Genes
9%
Dexamethasone Treatment
9%
Suckling Mice
9%
Liver
9%
Taselisib
9%
Postmenopausal Women
9%
Interobserver Agreement
9%
Risk Management Framework
9%
Everyday Practices
9%
Placebo
9%
Cancer Clinical Trials
9%
Placebo-controlled
9%
HER2-positive
9%
Latin American Women
9%
LORELEI
9%
Estrogen Receptor-positive
9%
Randomized Double-blind
9%
Letrozole
9%
Metastatic Breast Cancer
9%
Action Program
9%
Latin American Studies
9%
Residual Cancer Burden
9%
Esperanza
9%
Cancer Therapy
9%
Disease-free Survival
9%
Human Epidermal Growth Factor Receptor
9%
Prognostic Implications
9%
Integrated Missions
9%
Brain Metastases
9%
Newly Diagnosed
9%
American Women
9%
Breast Cancer Survival
9%
Pineal Region
9%
Breast Cancer Treatment
9%
Breast Cancer Diagnosis
9%
MicroRNA
9%
Circulating Tumor DNA (ctDNA)
9%
Latinas
7%
PIK3CA
7%
HMG-CoA Synthase
7%
Radiotherapy
7%
Breast Cancer Risk
7%
Hormone Receptor-negative
7%
CD4+
7%
Colombia
7%
Mexico
7%
MammaPrint
6%
Adjuvant Chemotherapy
6%
Hazard Ratio
6%
Medicine and Dentistry
Breast Cancer
90%
Tumor Infiltrating Lymphocyte
81%
Biological Marker
37%
Oncology
29%
Immunoglobulin
28%
Triple Negative Breast Cancer
25%
Stromal Tumor
20%
Neoplasm
20%
Clinical Trial
19%
Minimal Residual Disease
19%
Malignant Neoplasm
13%
Pathologist
12%
Neoadjuvant Therapy
11%
Estrogen Receptor
10%
Neoadjuvant Chemotherapy
10%
Glioblastoma
10%
Immunocompetent Cell
10%
Prognostic Factor
10%
Metastatic Breast Cancer
9%
Carcinoma in Situ
9%
Cancer
9%
Exon
9%
Programmed Death-Ligand 1
9%
Cancer Therapy
9%
Postmenopause
9%
Taselisib
9%
Placebo
9%
Letrozole
9%
Brain Metastasis
9%
microRNA
9%
Circulating Tumor DNA
9%
Disease
8%
Cancer Control
7%
Radiation Therapy
6%